Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Aytu BioScience to Present at Two Upcoming Investor Conferences

Aytu BioScience Inc.
Posted on: 14 Sep 16

PR Newswire

ENGLEWOOD, Colo., Sept. 14, 2016

ENGLEWOOD, Colo., Sept. 14, 2016 /PRNewswire/ -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it will present at two upcoming investor conferences in September 2016.

Aytu management will provide an overview of the company's business during live presentations, and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences.

Conference Details:

Event: Aegis 2016 Annual Growth Conference
Date: Wednesday, September 21, 2016
Time: 11:00am – 11:30am (Pacific Time) 
Location: The Encore at Wynn, Las Vegas

Event: Oktober INVESTfest in partnership with Joseph Gunnar
Date: Wednesday, September 28, 2016
Time: 8:45am – 9:10am (Eastern Time)
Location: The New York Academy of Sciences, New York 

About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The company currently markets three products: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging, and Primsol® (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Additionally, Aytu is developing MiOXSYS™, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets. For more information visit aytubio.com.

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aytu-bioscience-to-present-at-two-upcoming-investor-conferences-300327747.html

SOURCE Aytu BioScience Inc.

PR Newswire
www.prnewswire.com

Last updated on: 14/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.